Cargando…
Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist
BACKGROUND: Vitamin K antagonists are commonly used for the prevention of thromboembolic events. Patient self-monitoring of vitamin K antagonists has proved superior to usual care. Dabigatran has been shown, relative to warfarin, to reduce thromboembolic events without increasing bleeding. METHODS:...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515878/ https://www.ncbi.nlm.nih.gov/pubmed/26215871 http://dx.doi.org/10.1186/s12913-015-0934-9 |
_version_ | 1782382981284888576 |
---|---|
author | Carles, Misericòrdia Brosa, Max Souto, Juan Carlos Garcia-Alamino, Josep Maria Guyatt, Gordon Alonso-Coello, Pablo |
author_facet | Carles, Misericòrdia Brosa, Max Souto, Juan Carlos Garcia-Alamino, Josep Maria Guyatt, Gordon Alonso-Coello, Pablo |
author_sort | Carles, Misericòrdia |
collection | PubMed |
description | BACKGROUND: Vitamin K antagonists are commonly used for the prevention of thromboembolic events. Patient self-monitoring of vitamin K antagonists has proved superior to usual care. Dabigatran has been shown, relative to warfarin, to reduce thromboembolic events without increasing bleeding. METHODS: We constructed a Markov model to compare vitamin K self-monitoring strategies to dabigatran including effectiveness and costs of monitoring and complications (thromboembolism and major bleeding). The model was used to project the incidence of these complications, life years, quality-adjusted life years, and health system costs with anticoagulant treatment throughout life. The analysis was conducted from the health system perspective and from the societal perspective. RESULTS: Low quality evidence suggests that self-monitoring is at least as effective as dabigatran for the outcomes of thrombosis, bleeding and death. Moderate quality evidence that patient self-monitoring is more effective than other forms of monitoring degree of anticoagulation with vitamin K antagonists, reducing the relative risk of thromboembolism by 41 % and death by 34 %. The cost per quality adjusted year gained relative to other warfarin monitoring strategies is well below 30,000 € in the short term, and is a dominant alternative from the fourth year. In comparison with dabigatran, the lower annual cost and its equivalence in terms of effectiveness made self-monitoring the dominant option. These results were confirmed in the probabilistic sensitivity analysis. CONCLUSIONS: We have moderate quality evidence that self-monitoring of vitamin K antagonists is a cost-effective alternative compared with hospital and primary care monitoring, and low quality evidence, compared with dabigatran. Our analyses contrast with the available cost analysis of dabigatran and usual care of anticoagulated patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-015-0934-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4515878 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45158782015-07-28 Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist Carles, Misericòrdia Brosa, Max Souto, Juan Carlos Garcia-Alamino, Josep Maria Guyatt, Gordon Alonso-Coello, Pablo BMC Health Serv Res Research Article BACKGROUND: Vitamin K antagonists are commonly used for the prevention of thromboembolic events. Patient self-monitoring of vitamin K antagonists has proved superior to usual care. Dabigatran has been shown, relative to warfarin, to reduce thromboembolic events without increasing bleeding. METHODS: We constructed a Markov model to compare vitamin K self-monitoring strategies to dabigatran including effectiveness and costs of monitoring and complications (thromboembolism and major bleeding). The model was used to project the incidence of these complications, life years, quality-adjusted life years, and health system costs with anticoagulant treatment throughout life. The analysis was conducted from the health system perspective and from the societal perspective. RESULTS: Low quality evidence suggests that self-monitoring is at least as effective as dabigatran for the outcomes of thrombosis, bleeding and death. Moderate quality evidence that patient self-monitoring is more effective than other forms of monitoring degree of anticoagulation with vitamin K antagonists, reducing the relative risk of thromboembolism by 41 % and death by 34 %. The cost per quality adjusted year gained relative to other warfarin monitoring strategies is well below 30,000 € in the short term, and is a dominant alternative from the fourth year. In comparison with dabigatran, the lower annual cost and its equivalence in terms of effectiveness made self-monitoring the dominant option. These results were confirmed in the probabilistic sensitivity analysis. CONCLUSIONS: We have moderate quality evidence that self-monitoring of vitamin K antagonists is a cost-effective alternative compared with hospital and primary care monitoring, and low quality evidence, compared with dabigatran. Our analyses contrast with the available cost analysis of dabigatran and usual care of anticoagulated patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-015-0934-9) contains supplementary material, which is available to authorized users. BioMed Central 2015-07-28 /pmc/articles/PMC4515878/ /pubmed/26215871 http://dx.doi.org/10.1186/s12913-015-0934-9 Text en © Carles et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Carles, Misericòrdia Brosa, Max Souto, Juan Carlos Garcia-Alamino, Josep Maria Guyatt, Gordon Alonso-Coello, Pablo Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist |
title | Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist |
title_full | Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist |
title_fullStr | Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist |
title_full_unstemmed | Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist |
title_short | Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist |
title_sort | cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin k antagonist |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515878/ https://www.ncbi.nlm.nih.gov/pubmed/26215871 http://dx.doi.org/10.1186/s12913-015-0934-9 |
work_keys_str_mv | AT carlesmisericordia costeffectivenessanalysisofdabigatranandanticoagulationmonitoringstrategiesofvitaminkantagonist AT brosamax costeffectivenessanalysisofdabigatranandanticoagulationmonitoringstrategiesofvitaminkantagonist AT soutojuancarlos costeffectivenessanalysisofdabigatranandanticoagulationmonitoringstrategiesofvitaminkantagonist AT garciaalaminojosepmaria costeffectivenessanalysisofdabigatranandanticoagulationmonitoringstrategiesofvitaminkantagonist AT guyattgordon costeffectivenessanalysisofdabigatranandanticoagulationmonitoringstrategiesofvitaminkantagonist AT alonsocoellopablo costeffectivenessanalysisofdabigatranandanticoagulationmonitoringstrategiesofvitaminkantagonist |